nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.03.2011 | Original Article

Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens

verfasst von: Huanfa Yi, Xiaofei Yu, Chunqing Guo, Masoud H. Manjili, Elizabeth A. Repasky, Xiang-Yang Wang

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

In this study, we report a novel treatment strategy that could potentially be used to improve efficacy of adoptive cell therapy for patients with prostate cancer. We show that female C57BL/6 mice are able to effectively reject two syngeneic prostate tumors (TRAMP-C2 and RM1) in a T cell-dependent manner. The protective antitumor immunity appears to primarily involve T cell responses reactive against general prostate tumor/tissue antigens, rather than simply to male-specific H-Y antigen. For the first time we show that adoptive transfer of lymphocytes from TRAMP-C2-primed or naïve female mice effectively control prostate tumor growth in male mice, when combined with host pre-conditioning (i.e., non-myeloablative lymphodepletion) and IL-2 administration. No pathological autoimmune response was observed in the treated tumor-bearing male mice. Our studies provide new insights regarding the immune-mediated recognition of male-specific tissue, such as the prostate, and may offer new immunotherapy treatment strategies for advanced prostate cancer.

Pardoll DM (2002) Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2(4):227–238CrossRefPubMed

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9):909–915CrossRefPubMed

June CH (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117(5):1204–1212. doi:10.1172/JCI31446 CrossRefPubMed

Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409–417PubMed

de la Luz Garcia-Hernandez M, Gray A, Hubby B, Klinger OJ, Kast WM (2008) Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68(3):861–869. doi:10.1158/0008-5472.can-07-0445 CrossRef

Kuratsukuri K, Sone T, Wang CY, Nishisaka N, Jones RF, Haas GP (2002) Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the c-terminal end of PSMA. Int J Cancer 102(3):244–249CrossRefPubMed

Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23):3894–3903PubMed

Garcia-Hernandez MdlL, Gray A, Hubby B, Kast WM (2007) In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67(3):1344–1351. doi:10.1158/0008-5472.can-06-2996 CrossRef

Mathis D, Benoist C (2010) Levees of immunological tolerance. Nat Immunol 11(1):3–6CrossRefPubMed

10.

Walker LSK, Abbas AK (2002) The enemy within: keeping self-reactive t cells at bay in the periphery. Nat Rev Immunol 2(1):11–19CrossRefPubMed

11.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales M-A, Altan-Bonnet G, Wolchok JD, Houghton AN (2009) Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206(4):849–866. doi:10.1084/jem.20081382 CrossRefPubMed

12.

Tarassoff CP, Arlen PM, Gulley JL (2006) Therapeutic vaccines for prostate cancer. Oncologist 11(5):451–462. doi:10.1634/theoncologist.11-5-451 CrossRefPubMed

13.

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569–580CrossRefPubMed

14.

Labarthe MC, Theocharous P, Russell N, Todryk S, Bangma C, Thraves P, Dalgleish AG, Whelan MA (2008) A novel murine model of allogeneic vaccination against prostate cancer. Cancer Immunol Immunother 57(4):453–465. doi:10.1007/s00262-007-0384-2 CrossRefPubMed

15.

Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC (1995) Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52(5):403–413CrossRefPubMed

16.

Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325–3330PubMed

17.

Yi H, Yu X, Gao P, Wang Y, Baek SH, Chen X, Kim HL, Subjeck JR, Wang XY (2009) Pattern recognition scavenger receptor SRA/CD204 down-regulates toll-like receptor 4 signaling-dependent CD8 T-cell activation. Blood 113(23):5819–5828. doi:blood-2008-11-190033[pii] CrossRefPubMed

18.

Morales JK, Kmieciak M, Graham L, Feldmesser M, Bear HD, Manjili MH (2009) Adoptive transfer of her2/neu-specific t cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 58(6):941–953. doi:10.1007/s00262-008-0609-z CrossRefPubMed

19.

Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907–912. doi:10.1084/jem.20050732 CrossRefPubMed

20.

Gao P, Sun X, Chen X, Wang Y, Foster BA, Subjeck J, Fisher PB, Wang XY (2008) Secretable chaperone grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/il-24. Cancer Res 68(10):3890–3898CrossRefPubMed

21.

Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DEH (1999) Steap: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 96(25):14523–14528CrossRefPubMed

22.

Simpson E, Scott D, James E, Lombardi G, Cwynarski K, Dazzi F, Millrain M, Dyson PJ (2001) Minor h antigens: genes and peptides. Eur J Immunogenet 28(5):505–513CrossRefPubMed

23.

Millrain M, Chandler P, Dazzi F, Scott D, Simpson E, Dyson PJ (2001) Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol 167(7):3756–3764PubMed

24.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346–2357. doi:10.1200/jco.2005.00.240 CrossRefPubMed

25.

Wrzesinski C, Restifo NP (2005) Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 17(2):195–201CrossRefPubMed

26.

Yang D, Holt GE, Velders MP, Kwon ED, Kast WM (2001) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61(15):5857–5860PubMed

27.

Rodeberg DA, Nuss RA, Elsawa SF, Celis E (2005) Recognition of six-transmembrane epithelial antigen of the prostate expressing tumor cells by peptide antigen induced cytotoxic T lymphocytes. Clin Cancer Res 11(12):4545–4552. doi:10.1158/1078-0432.ccr-04-2235 CrossRefPubMed

28.

Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR (2004) Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 103(1):347–352. doi:10.1182/blood-2003-07-2603 CrossRefPubMed

29.

Weinhold M, Sommermeyer D, Uckert W, Blankenstein T (2007) Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol 179(8):5534–5542PubMed

30.

Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383CrossRefPubMed

31.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11):750–758CrossRefPubMed

32.

Childs RW, Barrett J (2004) Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 55(1):459–475. doi:10.1146/annurev.med.55.091902.104511 CrossRefPubMed

33.

Kausche S, Wehler T, Schnurer E, Lennerz V, Brenner W, Melchior S, Grone M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W (2006) Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells. Cancer Res 66(23):11447–11454CrossRefPubMed

34.

Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP (2008) Adoptive transfer of allogeneic tumor-specific t cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 112(12):4746–4754CrossRefPubMed

35.

Valenzuela JO, Iclozan C, Hossain MS, Prlic M, Hopewell E, Bronk CC, Wang J, Celis E, Engelman RW, Blazar BR, Bevan MJ, Waller EK, Yu X-Z, Beg AA (2009) PkCtheta¸ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest 119(12):3774–3786CrossRefPubMed

36.

Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102(27):9571–9576CrossRefPubMed

37.

Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR (2008) Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118(1):294–305. doi:10.1172/JCI32103 CrossRefPubMed

38.

Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP (2009) Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 106(41):17469–17474CrossRefPubMed

39.

Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ Jr, Levine BL, Carroll RG, Riley JL, June CH (2008) Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 42(1–3):182–196. doi:10.1007/s12026-008-8070-9 CrossRefPubMed

40.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126–129CrossRefPubMed

Titel: Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens
verfasst von: Huanfa Yi
Xiaofei Yu
Chunqing Guo
Masoud H. Manjili
Elizabeth A. Repasky
Xiang-Yang Wang
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2011
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-010-0939-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma

Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production

Suppression of T-cell responses by tumor metabolites

A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie